Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03782064 · OUTCOME

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma · Source last updated 2023-06-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
2 years

What was measured

We evaluated the number of patients who developed a related adverse event as assessed by the CTCAE version 4.0.

Analysis population: Patients who developed treatment-related adverse events

Groups in this outcome

Nivolumab+DC/Myeloma Fusions/GM-CSF

* Nivolumab will be given every two weeks * The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle Nivolumab: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells. DC/myeloma fusions/GM-CSF: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Nivolumab+DC/Myeloma Fusions/GM-CSF2

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Nivolumab+DC/Myeloma Fusions/GM-CSF2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        2
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
We evaluated the number of patients who developed a related adverse event as assessed by the CTCAE version 4.0.
groups
  1. description
    * Nivolumab will be given every two weeks * The DC/myeloma fusion vaccine/GM-CSF is administered 4 days per cycle Nivolumab: Nivolumab is a monoclonal antibody. Antibodies are part of your immune system; they are a type of protein that protects your body against foreign invaders, called antigens, by grabbing hold of antigens to stop them from invading your system. Nivolumab has been shown to react against cancer cells, including MM cells. DC/myeloma fusions/GM-CSF: The DC/MM vaccine is an investigational agent that tries to help the immune system recognize and fight against cancer cells, utilizing unique markers.
    id
    OG000
    title
    Nivolumab+DC/Myeloma Fusions/GM-CSF
param Type
COUNT_OF_PARTICIPANTS
population Description
Patients who developed treatment-related adverse events
reporting Status
POSTED
time Frame
2 years
title
Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice